Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSX:BLCO)

20.42 +0.30 (+1.49%)
Streaming Delayed Price Updated: 3:50 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,200
Open 20.20
Bid (Size) 20.52 (3)
Ask (Size) 20.56 (1)
Prev. Close 20.12
Today's Range 20.11 - 20.42
52wk Range 18.11 - 29.37
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
-21.3%
-21.3%
1 Month
-11.6%
-11.6%
3 Month
-21.3%
-21.3%
6 Month
-20.9%
-20.9%
1 Year
-12.1%
-12.1%

More News

Read More
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Responds to Rumors of a Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Third-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Second-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
From Bausch + Lomb Corporation
Via Business Wire
Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
From Bausch + Lomb Corporation
Via Business Wire

Frequently Asked Questions

Is BLCO publicly traded?
Yes, BLCO is publicly traded.
What exchange does BLCO trade on?
BLCO trades on the Toronto Stock Exchange
What is the ticker symbol for BLCO?
The ticker symbol for BLCO is BLCO on the Toronto Stock Exchange
What is the current price of BLCO?
The current price of BLCO is 20.42
When was BLCO last traded?
The last trade of BLCO was at 04/02/25 03:50 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.